

adding angiotensin II to sperm, administering angiotensin II to a male mammalian subject in need thereof, or delivering angiotensin II to a reproductive tract of a female mammalian subject to be inseminated.

- a2  
cont*
87. [NEW] The method of Claim 86, wherein the angiotensin II is administered in combination with a pharmaceutically-suitable carrier and the angiotensin II is present in an amount of from about 0.5 nM to about 100 nM.

---

REMARKS

Claim 1 is amended herein. Claims 2-33 have been canceled. Claims 34-87 are newly added herein. All of the newly added claims find explicit support from Claims 1-33 as presented in the priority PCT application. No new matter is added.

Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is earnestly solicited.

If any questions regarding the application arise, please contact the undersigned attorney. Telephone calls related to this application are welcomed and encouraged. The Commissioner is authorized to charge any fees or credit any overpayments relating to this application to deposit account number 18-2055.

For the Applicant,

*[Signature]*  
Joseph T. Leone, Reg. No. 37,170  
DEWITT ROSS & STEVENS S.C.  
Firststar Financial Centre  
8000 Excelsior Drive, Suite 401  
Madison, Wisconsin 53717-1914  
Telephone: (608) 831-2100  
Facsimile: (608) 831-2106

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): FRASER, Lynn Repsis

Atty. Docket: 78104.037

Title: STIMULATION OF SPERM FUNCTION

**"MARKED UP" CLAIMS AS AMENDED, 37 CFR §1.121(c)(1)(ii)**

1. [AMENDED] A [combined] medication for increasing [the] capacitation of mammalian sperm, the medication comprising a combination of two or more agents [each of which is] selected from the [groups] group consisting of [(1)] calcitonin, [(2)] angiotensin II, and [(3)] a modulator of adenosine receptor activity.